FitLife Brands, Inc. (NASDAQ: FTLF) – Q1 2026 Earnings
FitLife Brands, Inc. (NASDAQ: FTLF) – Q1 2026 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
FitLife Brands is a nutritional supplements and wellness products company selling more than 500 products through online channels, Amazon, and retail/wholesale partners. The company’s revenue is now split between Legacy FitLife brands and the recently acquired Irwin business, which shifted the company toward a larger wholesale mix but also brought lower gross margins, supply chain issues, and integration complexity. Q1 2026 looked strong on the surface because revenue rose 59% year over year to $25.3 million, but the real story is mixed: growth was acquisition-driven, Legacy FitLife declined 22%, adjusted EBITDA fell 3%, and management is trying to offset consumer weakness with Amazon growth, debt reduction, new Kroger distribution, and margin improvement initiatives.
The press release frames Q1 as a challenging but improving quarter, while the call adds more useful investor context: April orders were stronger than reported revenue timing suggests, Irwin Amazon subscribers are scaling quickly, MusclePharm is being managed for margin rather than low-quality revenue, and the Kroger launch is more strategically important than the press release alone makes clear.
Quarterly Results
Earnings Release Date: May 14, 2026
Stock Price: $9.53
Market Cap: $89.5 million
Q1 2026 sales of $25.3 million vs $15.9 million in the prior year
Q1 2026 GAAP Diluted EPS of $0.17 vs $0.20 in the prior year
Quick Takeaway
FitLife Brands is in an acquisition integration and stabilization phase, trying to turn the Irwin acquisition into a growth platform while repairing Legacy FitLife weakness. The main positives are Irwin’s Amazon ramp, rapid subscriber growth, Kroger distribution for MusclePharm, debt paydown, and potential margin recovery from inventory dating and supply chain improvements. The main concerns are that reported revenue growth is acquisition-driven, Legacy FitLife is declining, Irwin organic revenue is down, adjusted EBITDA declined despite much higher revenue, and Amazon algorithm issues remain unresolved.
Press Release vs Call Transcript Comparison
FitLife’s Q1 looks like a transitional quarter where the company is absorbing the Irwin acquisition while dealing with consumer weakness, Amazon disruption, and legacy brand softness. The press release gives the financial facts, but the call is more valuable for judging whether the weakness is temporary. Management’s tone was not promotional; it acknowledged the quarter was challenging, but tried to point investors toward sequential improvement, Amazon subscriber growth, retail expansion, and debt reduction.
The key investment debate is whether FitLife is a temporarily pressured consolidator with multiple self-help levers, or a company whose acquisition-driven revenue growth is masking deterioration in the core business. The numbers alone lean mixed-to-negative because adjusted EBITDA declined despite 59% revenue growth. The call adds enough operating detail to make the recovery case more credible, especially around Irwin Amazon, Kroger, and margin improvement, but the burden of proof remains on Q2 and Q3 execution.
Investor Underappreciation Signals
✅ Irwin Amazon subscriber ramp — Irwin’s Amazon revenue growth was already visible in the press release, but the call’s disclosure that subscribers rose from roughly 500 to over 5,700 makes the channel look more recurring and potentially more durable than investors may assume.
✅ April order strength hidden by revenue timing — The call disclosed that April was the strongest sales order month of the year, but elevated shipments in transit delayed revenue recognition, which means investors looking only at reported April revenue commentary may miss underlying demand improvement.
✅ Kroger launch is more than a shelf placement — The press release framed Kroger as a two-SKU launch, but the call revealed a 700–800 store rollout supported by coupons, geotargeted connected TV, and category experience, making it a more serious retail catalyst than the headline suggests.
✅ MusclePharm margin reset — MusclePharm revenue is down partly because management is walking away from low-margin international protein sales, and investors may overlook that a smaller revenue base could produce better contribution if online and higher-margin retail channels grow.
✅ Inventory dating could aid margin recovery — The call’s discussion of three-year product dating and reduced obsolescence expense points to a quiet margin lever that is not obvious from the press release’s headline gross margin decline.
✅ Debt paydown can compound equity value — FitLife reduced net debt during a difficult quarter, and continued free-cash-flow-driven debt reduction could matter more to equity holders if operating trends stabilize.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
The transcript does not mention U.S. tariffs, trade policy, tariff-related cost pressure, supply chain relocation, contract renegotiation, tariff-driven price increases, or tariff impacts on profitability.
The closest related issue is supply chain disruption at Irwin, specifically out-of-stock situations that management estimated caused $1.0 million to $1.5 million of lost revenue. However, management did not attribute those issues to tariffs or trade policy. Based only on the transcript, tariff risk is not a disclosed investment factor for this quarter.
Investors should still verify supply chain exposure elsewhere, especially if the company sources ingredients, finished goods, packaging, or manufacturing from regions affected by tariffs. The transcript alone does not provide enough detail to assess tariff sensitivity.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
In Q4 2025, FitLife was explaining the new shape of the company after Irwin: larger, more wholesale-heavy, lower margin, more complex, and facing broad consumer and Amazon-related pressure. Management laid out a recovery plan but was cautious, declining formal guidance because it did not know how long the weakness would last or how quickly internal fixes would work.By Q1 2026, the story had shifted from diagnosis to early execution. The financial headline remained mixed — revenue growth was acquisition-driven, Legacy FitLife weakened further, and adjusted EBITDA declined — but management had more concrete proof points: Irwin Amazon continued scaling, subscriber growth accelerated, gross margins improved sequentially, debt was reduced, inventory dating work progressed, and Kroger emerged as a meaningful MusclePharm retail opportunity. The investment narrative is now a test of whether those self-help levers can outweigh organic weakness in the core business.
Year-over-year comparison
In Q1 2025, FitLife was still positioned as a lean, profitable, low-leverage supplement platform with an M&A pipeline, strong balance sheet, online-channel profitability, and possible index-inclusion catalyst. The company had issues — MRC weakness, MusclePharm execution, tariffs, and customer timing — but management still sounded confident that organic revenue growth was achievable.
By Q1 2026, FitLife had transformed into a larger but more complicated company. The Irwin acquisition nearly reset the entire story: revenue scale improved, but leverage rose, gross margin fell, adjusted EBITDA declined, and Legacy FitLife weakened materially. The narrative is now about execution — growing Irwin on Amazon, resolving out-of-stocks, improving margins, launching MusclePharm into Kroger, and using cash flow to reduce debt. The company has more upside levers than a year ago, but also more operational risk and less margin for error.